IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.896
EU - Europa 3.213
AS - Asia 1.329
Continente sconosciuto - Info sul continente non disponibili 27
OC - Oceania 13
SA - Sud America 9
AF - Africa 4
Totale 26.491
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.878
CN - Cina 1.135
SE - Svezia 1.092
IT - Italia 554
UA - Ucraina 394
FI - Finlandia 347
GB - Regno Unito 280
DE - Germania 261
FR - Francia 106
VN - Vietnam 86
BE - Belgio 52
IN - India 45
IE - Irlanda 39
NL - Olanda 25
EU - Europa 24
IR - Iran 17
CA - Canada 15
SG - Singapore 11
AU - Australia 10
ES - Italia 8
GR - Grecia 8
HK - Hong Kong 8
RO - Romania 8
PT - Portogallo 6
RU - Federazione Russa 6
SA - Arabia Saudita 6
BG - Bulgaria 5
CZ - Repubblica Ceca 5
KR - Corea 5
IL - Israele 4
AR - Argentina 3
BD - Bangladesh 3
BR - Brasile 3
NZ - Nuova Zelanda 3
PL - Polonia 3
TR - Turchia 3
A1 - Anonimo 2
CH - Svizzera 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
JP - Giappone 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
GL - Groenlandia 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
SY - Repubblica araba siriana 1
Totale 26.491
Salva come PNG Salva come JPEG
Città #
Fairfield 3.782
Woodbridge 2.606
Houston 1.761
Chandler 1.723
Ashburn 1.720
Seattle 1.491
Cambridge 1.275
Wilmington 1.173
Ann Arbor 1.080
Jacksonville 1.001
Nyköping 846
Lawrence 421
Roxbury 405
Nanjing 351
Des Moines 280
Beijing 261
Princeton 234
Bari 209
New York 184
San Diego 165
Boardman 151
Inglewood 142
Brooklyn 95
Dong Ket 85
Norwalk 85
Shenyang 84
Hebei 81
Nanchang 81
Dearborn 73
London 67
Tianjin 64
Jiaxing 59
Paris 59
Brussels 49
Changsha 42
Dublin 37
Los Angeles 36
Washington 32
Pune 30
Marseille 24
Falls Church 23
Mottola 22
Redwood City 19
Jinan 18
Kilburn 18
San Mateo 18
Taranto 18
Bisceglie 17
Helsinki 17
Leawood 17
Zhengzhou 16
Rome 15
Augusta 13
Hefei 13
Catania 12
Milan 12
Monmouth Junction 12
Auburn Hills 11
Chiswick 11
Indiana 11
San Francisco 10
Guangzhou 9
Prescot 9
Ardabil 8
Hong Kong 8
Kunming 8
Toronto 8
Chicago 7
Edinburgh 7
Singapore 7
Grafing 6
Hounslow 6
Mumbai 6
Redmond 6
St Louis 6
Trani 6
Jeddah 5
Kansas City 5
Ningbo 5
Taizhou 5
Acton 4
Amsterdam 4
Bitonto 4
Cerignola 4
Dallas 4
Madrid 4
Melbourne 4
Mendicino 4
Seelze 4
St Albans 4
Stockholm 4
West Jordan 4
Athens 3
Atlanta 3
Brno 3
Chengdu 3
Chieti 3
Florence 3
Hanover 3
Islington 3
Totale 22.866
Salva come PNG Salva come JPEG
Nome #
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 158
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 155
Assessing response to interferon-β in a multicenter dataset of patients with MS 152
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 138
Prognostic indicators in pediatric clinically isolated syndrome 130
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 129
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 128
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 126
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 123
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 121
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 118
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 116
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 116
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 115
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 114
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 113
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 113
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 109
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 109
null 109
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 107
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 107
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 106
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 106
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 105
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 105
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 104
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 102
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 102
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 100
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 100
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 100
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 99
Age-related changes of serum N-acetyl-aspartate in healthy controls. 98
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study 97
Treating multiple sclerosis with natalizumab. 97
Comparative efficacy of switching to natalizumab in active multiple sclerosis 97
Multiple sclerosis registries in Europe – An updated mapping survey 97
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 96
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. 96
Psychosocial issue in children and adolescents with multiple sclerosis 96
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 96
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies 94
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 93
The role of sexual dysfunction and attachment style in migraine related quality of life 93
Treatment decisions in multiple sclerosis-insights from real-world observational studies 93
Defining secondary progressive multiple sclerosis 93
Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 92
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. 92
A rare case of multiple sclerosis and McArdle disease 92
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 92
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 92
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 92
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 92
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 91
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 91
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 91
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 91
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 91
Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis 90
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 90
null 90
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 89
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society 89
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 89
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 89
Long term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 88
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 88
Can databasing optimise patient care? 87
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 87
Natalizumab discontinuation and disease restart in pregnancy: A case series 87
The relationship between group A streptococcal infections and Tourette syndrome: a study on a large service-based cohort 86
Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation 86
The brief international cognitive assessment for multiple sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population 86
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 86
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 86
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study 85
Safety profile of Tysabri: international risk management plan 85
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 85
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration 85
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 85
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study 85
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 85
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 85
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis 84
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 84
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study 84
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 84
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study 83
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 83
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 83
Age-related disability in multiple sclerosis 83
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis 83
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis 82
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. 82
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study 82
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 82
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 82
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans 82
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. 81
Totale 9.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.112 0 0 0 0 0 0 0 0 0 0 1.080 1.032
2019/20207.776 1.176 443 292 747 838 525 755 727 875 414 786 198
2020/20215.470 412 298 469 537 793 342 473 398 399 628 406 315
2021/20223.141 232 397 46 73 138 282 170 164 232 202 504 701
2022/20234.540 740 480 286 406 583 547 65 529 660 29 122 93
2023/20241.359 145 295 105 109 138 341 60 59 31 62 14 0
Totale 27.854